Psoriasis and Atherothrombotic Diseases: Disease-Specific and Non–Disease-Specific Risk Factors

 

 Buy Article Permissions and Reprints

ABSTRACT

Psoriasis is a chronic inflammatory, immune-mediated skin disease affecting 2 to 3% of the general population and may cause significant quality-of-life impairment. Psoriasis and psoriatic arthritis are associated with increased atherothrombotic diseases, including myocardial infarction, deep venous thrombosis, and reduced life span. Both disease-specific and non–disease-specific risk factors are likely to fuel one another in deleterious vicious circles. Disease-specific risk factors are those that are a direct consequence of psoriasis inflammation and include hyperhomocysteinemia, elevated C-reactive protein, elevated blood inflammatory cytokines, and platelet hyperactivity. Non–disease-specific risk factors include insulin resistance/diabetes, obesity, dyslipidemia, hypertension, metabolic syndrome, and habitual tobacco smoking. The presence of cardio-metabolic comorbidities has also relevant implication in the therapy and global approach to patients with psoriasis. Traditional systemic antipsoriatic agents frequently negatively affect cardio-metabolic comorbidities and may have important interactions with drugs commonly used by psoriasis patients. Thus, patients with psoriasis should be treated effectively and encouraged to aggressively correct their modifiable cardiovascular risk factors.

REFERENCES

• 1 Gudjonsson J E, Elder J T. Psoriasis: epidemiology.  Clin Dermatol. 2007;  25 535-546
  CrossrefPubMedGoogle Scholar
• 2 Nestle F O. Psoriasis.  Curr Dir Autoimmun. 2008;  10 65-75
  PubMedGoogle Scholar
• 3 Muto M, Ohmura A, Hamamoto Y et al.. Generalized pustular psoriasis: strategy for identification of psoriasis susceptibility gene.  Arch Dermatol Res. 2003;  295(Suppl 1) S60-S62
  PubMedGoogle Scholar
• 4 Lowes M A, Bowcock A M, Krueger J G. Pathogenesis and therapy of psoriasis.  Nature. 2007;  445 866-873
  CrossrefPubMedGoogle Scholar
• 5 Ottaviani C, Nasorri F, Bedini C, de Pità O, Girolomoni G, Cavani A. CD56brightCD16(-) NK cells accumulate in psoriatic skin in response to CXCL10 and CCL5 and exacerbate skin inflammation.  Eur J Immunol. 2006;  36 118-128
  CrossrefPubMedGoogle Scholar
• 6 Bachelez H. Immunopathogenesis of psoriasis: recent insights on the role of adaptive and innate immunity.  J Autoimmun. 2005;  25(Suppl) 69-73
  CrossrefPubMedGoogle Scholar
• 7 Mee J B, Johnson C M, Morar N, Burslem F, Groves R W. The psoriatic transcriptome closely resembles that induced by interleukin-1 in cultured keratinocytes: dominance of innate immune responses in psoriasis.  Am J Pathol. 2007;  171 32-42
  CrossrefPubMedGoogle Scholar
• 8 Sa S M, Valdez P A, Wu J et al.. The effects of IL-20 subfamily cytokines on reconstituted human epidermis suggest potential roles in cutaneous innate defense and pathogenic adaptive immunity in psoriasis.  J Immunol. 2007;  178 2229-2240
  PubMedGoogle Scholar
• 9 Conrad C, Boyman O, Tonel G et al.. Alpha1beta1 integrin is crucial for accumulation of epidermal T cells and the development of psoriasis.  Nat Med. 2007;  13 836-842
  PubMedGoogle Scholar
• 10 Blauvelt A. New concepts in the pathogenesis and treatment of psoriasis: key roles for IL-23, IL-17A and TGF-β1.  Expert Rev Dermatol. 2007;  2 69-78
  CrossrefPubMedGoogle Scholar
• 11 Bettelli E, Oukka M, Kuchroo V KT. T(H)-17 cells in the circle of immunity and autoimmunity.  Nat Immunol. 2007;  8 345-350
  CrossrefPubMedGoogle Scholar
• 12 Albanesi C, Cavani A, Girolomoni G. IL-17 is produced by nickel-specific T lymphocytes and regulates ICAM-1 expression and chemokine production in human keratinocytes: synergistic or antagonist effects with IFN-γ and TNF-α.  J Immunol. 1999;  162 494-502
  PubMedGoogle Scholar
• 13 Albanesi C, Scarponi C, Cavani A, Federici M, Nasorri F, Girolomoni G. Interleukin-17 is produced by both Th1 and Th2 lymphocytes, and modulates interferon-γ- and interleukin-4-induced activation of human keratinocytes.  J Invest Dermatol. 2000;  115 81-87
  CrossrefPubMedGoogle Scholar
• 14 Ma H L, Liang S, Li J et al.. IL-22 is required for Th17 cell-mediated pathology in a mouse model of psoriasis-like skin inflammation.  J Clin Invest. 2008;  118 597-607
  PubMedGoogle Scholar
• 15 Wolk K, Witte E, Wallace E et al.. IL-22 regulates the expression of genes responsible for antimicrobial defense, cellular differentiation, and mobility in keratinocytes: a potential role in psoriasis.  Eur J Immunol. 2006;  36 1309-1323
  CrossrefPubMedGoogle Scholar
• 16 Li J, Li D, Tan Z. The expression of interleukin-17, interferon-gamma, and macrophage inflammatory protein-3 alpha mRNA in patients with psoriasis vulgaris.  J Huazhong Univ Sci Technolog Med Sci. 2004;  24 294-296
  PubMedGoogle Scholar
• 17 Lowes M A, Kikuchi T, Fuentes-Duculan J et al.. Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells.  J Invest Dermatol. 2008;  128 1207-1211
  CrossrefPubMedGoogle Scholar
• 18 Lee E, Trepicchio W L, Oestreicher J L et al.. Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris.  J Exp Med. 2004;  199 125-130
  PubMedGoogle Scholar
• 19 Krueger G G, Langley R G, Leonardi C CNTO 1275 Psoriasis Study Group et al. A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis.  N Engl J Med. 2007;  356 580-592
  CrossrefPubMedGoogle Scholar
• 20 Papp K A, Langley R G, Lebwohl M PHOENIX 2 Study Investigators et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2).  Lancet. 2008;  371 1675-1684
  CrossrefPubMedGoogle Scholar
• 21 Kimball A B, Gordon K B, Langley R G, Menter A, Chartash E K, Valdes J. ABT-874 Psoriasis Study Investigators . Safety and efficacy of ABT-874, a fully human interleukin 12/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis: results of a randomized, placebo-controlled, phase 2 trial.  Arch Dermatol. 2008;  144 200-207
  CrossrefPubMedGoogle Scholar
• 22 Albanesi C, De Pità O, Girolomoni G. Resident skin cells in psoriasis: a special look at the pathogenetic functions of keratinocytes.  Clin Dermatol. 2007;  25 581-588
  CrossrefPubMedGoogle Scholar
• 23 Diluvio L, Vollmer S, Besgen P, Ellwart J W, Chimenti S, Prinz J C. Identical TCR beta-chain rearrangements in streptococcal angina and skin lesions of patients with psoriasis vulgaris.  J Immunol. 2006;  176 7104-7111
  CrossrefPubMedGoogle Scholar
• 24 Sugiyama H, Gyulai R, Toichi E et al.. Dysfunctional blood and target tissue CD4 + CD25high regulatory T cells in psoriasis: mechanism underlying unrestrained pathogenic effector T cell proliferation.  J Immunol. 2005;  174 164-173
  PubMedGoogle Scholar
• 25 Giustizieri M L, Mascia F, Frezzolini A et al.. Keratinocytes from patients with atopic dermatitis and psoriasis show a distinct chemokine production profile in response to T cell-derived cytokines.  J Allergy Clin Immunol. 2001;  107 871-877
  CrossrefPubMedGoogle Scholar
• 26 Stratis A, Pasparakis M, Rupec R A et al.. Pathogenic role for skin macrophages in a mouse model of keratinocyte-induced psoriasis-like skin inflammation.  J Clin Invest. 2006;  116 2094-2104
  CrossrefPubMedGoogle Scholar
• 27 Lande R, Gregorio J, Facchinetti V et al.. Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide.  Nature. 2007;  449 564-569
  CrossrefPubMedGoogle Scholar
• 28 Albanesi C, Scarponi C, Pallotta S et al.. Role of chemerin-R23 axis in the recruitment of plasmocitoid dendritic cells in psoriatic skin.  J Exp Med. 2009;  206 243-258
  PubMedGoogle Scholar
• 29 Lowes M A, Chamian F, Abello M V et al.. Increase in TNF-α and inducible nitric oxide synthase-expressing dendritic cells in psoriasis and reduction with efalizumab (anti-CD11a).  Proc Natl Acad Sci U S A. 2005;  102 19057-19062
  CrossrefPubMedGoogle Scholar
• 30 Alamanos Y, Voulgari P V, Drosos A A. Incidence and prevalence of psoriatic arthritis: a systematic review.  J Rheumatol. 2008;  35 1354-1358
  PubMedGoogle Scholar
• 31 Gisondi P, Girolomoni G, Sampogna F, Tabolli S, Abeni D. Prevalence of psoriatic arthritis and joint complaints in a large population of Italian patients hospitalised for psoriasis.  Eur J Dermatol. 2005;  15 279-283
  PubMedGoogle Scholar
• 32 Ozçakar L, Cetin A, Inanici F, Kaymak B, Gürer C K, Kölemen F. Ultrasonographical evaluation of the Achilles' tendon in psoriasis patients.  Int J Dermatol. 2005;  44 930-932
  CrossrefPubMedGoogle Scholar
• 33 Gisondi P, Tinazzi I, El-Dalati G et al.. Lower limb enthesopathy in patients with psoriasis without clinical signs of arthropathy: a hospital-based case-control study.  Ann Rheum Dis. 2008;  67 26-30
  CrossrefPubMedGoogle Scholar
• 34 Husted J A, Tom B D, Farewell V T, Schentag C T, Gladman D D. A longitudinal study of the effect of disease activity and clinical damage on physical function over the course of psoriatic arthritis: does the effect change over time?.  Arthritis Rheum. 2007;  56 840-849
  CrossrefPubMedGoogle Scholar
• 35 McDonald C J, Calabresi P. Psoriasis and occlusive vascular disease.  Br J Dermatol. 1978;  99 469-475
  PubMedGoogle Scholar
• 36 Mallbris L, Akre O, Granath F et al.. Increased risk for cardiovascular mortality in psoriasis inpatients but not in outpatients.  Eur J Epidemiol. 2004;  19 225-230
  PubMedGoogle Scholar
• 37 Gelfand J M, Neimann A L, Shin D B, Wang X, Margolis D J, Troxel A B. Risk of myocardial infarction in patients with psoriasis.  JAMA. 2006;  296 1735-1741
  CrossrefPubMedGoogle Scholar
• 38 Ludwig R J, Herzog C, Rostock A et al.. Psoriasis: a possible risk factor for development of coronary artery calcification.  Br J Dermatol. 2007;  156 271-276
  CrossrefPubMedGoogle Scholar
• 39 Cassano N, Buquicchio R, Ranieri V, Loconsole F, Vena G A. Is there an association between antiphospholipid antibodies and psoriasis?.  J Biol Regul Homeost Agents. 2008;  22 207-210
  PubMedGoogle Scholar
• 40 Eldibany M M, Caprini J A. Hyperhomocysteinemia and thrombosis: an overview.  Arch Pathol Lab Med. 2007;  131 872-884
  PubMedGoogle Scholar
• 41 Malerba M, Gisondi P, Radaeli A, Sala R, Calzavara Pinton P G, Girolomoni G. Plasma homocysteine and folate levels in patients with chronic plaque psoriasis.  Br J Dermatol. 2006;  155 1165-1169
  CrossrefPubMedGoogle Scholar
• 42 Karabudak O, Ulusoy R E, Erikci A A, Solmazgul E, Dogan B, Harmanyeri Y. Inflammation and hypercoagulable state in adult psoriatic men.  Acta Derm Venereol. 2008;  88 337-340
  PubMedGoogle Scholar
• 43 Vanizor Kural B, Orem A, Cimşit G, Uydu H A, Yandi Y E, Alver A. Plasma homocysteine and its relationships with atherothrombotic markers in psoriatic patients.  Clin Chim Acta. 2003;  332 23-30
  CrossrefPubMedGoogle Scholar
• 44 Weger W, Hofer A, Stanger O et al.. The methylenetetrahydrofolate reductase 677C> T gene polymorphism is not associated with chronic plaque psoriasis.  Exp Dermatol. 2008;  17 748-751
  CrossrefPubMedGoogle Scholar
• 45 Nygård O, Refsum H, Ueland P M, Vollset S E. Major lifestyle determinants of plasma total homocysteine distribution: the Hordaland Homocysteine Study.  Am J Clin Nutr. 1998;  67 263-270
  PubMedGoogle Scholar
• 46 Scarpa R, Manguso F, D'Arienzo A et al.. Microscopic inflammatory changes in colon of patients with both active psoriasis and psoriatic arthritis without bowel symptoms.  J Rheumatol. 2000;  27 1241-1246
  PubMedGoogle Scholar
• 47 Rozen R. Molecular genetic aspects of hyperhomocysteinemia and its relation to folic acid.  Clin Invest Med. 1996;  19 171-178
  PubMedGoogle Scholar
• 48 Casas J P, Shah T, Hingorani A D, Danesh J, Pepys M B. C-reactive protein and coronary heart disease: a critical review.  J Intern Med. 2008;  264 295-314
  CrossrefPubMedGoogle Scholar
• 49 Montecucco F, Mach F. New evidences for C-reactive protein (CRP) deposits in the arterial intima as a cardiovascular risk factor.  Clin Interv Aging. 2008;  3 341-349
  PubMedGoogle Scholar
• 50 Ridker P M, Buring J E, Cook N R, Rifai N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14,719 initially healthy American women.  Circulation. 2003;  107 391-397
  CrossrefPubMedGoogle Scholar
• 51 Zacho J, Tybjaerg-Hansen A, Jensen J S, Grande P, Sillesen H, Nordestgaard B G. Genetically elevated C-reactive protein and ischemic vascular disease.  N Engl J Med. 2008;  359 1897-1908
  CrossrefPubMedGoogle Scholar
• 52 Chodorowska G, Wojnowska D, Juszkiewicz-Borowiec M. C-reactive protein and alpha2-macroglobulin plasma activity in medium-severe and severe psoriasis.  J Eur Acad Dermatol Venereol. 2004;  18 180-183
  CrossrefPubMedGoogle Scholar
• 53 Rocha-Pereira P, Santos-Silva A, Rebelo I, Figueiredo A, Quintanilha A, Teixeira F. The inflammatory response in mild and in severe psoriasis.  Br J Dermatol. 2004;  150 917-928
  CrossrefPubMedGoogle Scholar
• 54 Ohtsuka T. The relation between high-sensitivity C-reactive protein and maximum body mass index in patients with psoriasis.  Br J Dermatol. 2008;  158 1141-1143
  CrossrefPubMedGoogle Scholar
• 55 Sergeant A, Makrygeorgou A, Chan W C, Thorrat A, Burden D. C-reactive protein in psoriasis.  Br J Dermatol. 2008;  158 417-419
  PubMedGoogle Scholar
• 56 Ohtsuka T. The correlation between response to oral cyclosporin therapy and systemic inflammation, metabolic abnormality in patients with psoriasis.  Arch Dermatol Res. 2008;  300 545-550
  CrossrefPubMedGoogle Scholar
• 57 Strober B, Teller C, Yamauchi P et al.. Effects of etanercept on C-reactive protein levels in psoriasis and psoriatic arthritis.  Br J Dermatol. 2008;  159 322-330
  CrossrefPubMedGoogle Scholar
• 58 Serwin A B, Wasowicz W, Chodynicka B. Selenium supplementation, soluble tumor necrosis factor-alpha receptor type 1, and C-reactive protein during psoriasis therapy with narrowband ultraviolet B.  Nutrition. 2006;  22 860-864
  CrossrefPubMedGoogle Scholar
• 59 Kasperska-Zajac A, Brzoza Z, Rogala B. Platelet function in cutaneous diseases.  Platelets. 2008;  19 317-321
  CrossrefPubMedGoogle Scholar
• 60 Berrettini M, Parise P, Constantini V, Grasselli S, Nenci G G. Platelet activation in psoriasis.  Thromb Haemost. 1985;  53 195-197
  PubMedGoogle Scholar
• 61 Tamagawa-Mineoka R, Katoh N, Ueda E, Masuda K, Kishimoto S. Elevated platelet activation in patients with atopic dermatitis and psoriasis: increased plasma levels of thromboglobulin and platelet factor 4.  Allergol Int. 2008;  57 391-396
  CrossrefPubMedGoogle Scholar
• 62 Ludwig R J, Schultz J E, Boehncke W H et al.. Activated, not resting, platelets increase leukocyte rolling in murine skin utilizing a distinct set of adhesion molecules.  J Invest Dermatol. 2004;  122 830-836
  CrossrefPubMedGoogle Scholar
• 63 Vila L, Cullaré C, Solá J, Puig L, de Castellarnau C, de Moragas J M. Cyclooxygenase activity is increased in platelets from psoriatic patients.  J Invest Dermatol. 1991;  97 922-926
  CrossrefPubMedGoogle Scholar
• 64 Vila L, Solá J, Puig L, de Castellarnau C, de Moragas J M. Exogenous arachidonic acid metabolism in platelets from psoriatic patients.  Acta Derm Venereol. 1990;  70 110-114
  PubMedGoogle Scholar
• 65 Hayashi S, Shimizu I, Miyauchi H, Watanabe S. Increased platelet aggregation in psoriasis.  Acta Derm Venereol. 1985;  65 258-262
  PubMedGoogle Scholar
• 66 Kragballe K, Fallon J D. Increased aggregation and arachidonic acid transformation by psoriatic platelets: evidence that platelet-derived 12-hydroxy-eicosatetraenoic acid increases keratinocyte DNA synthesis in vitro.  Arch Dermatol Res. 1986;  278 449-453
  CrossrefPubMedGoogle Scholar
• 67 Libby P. Role of inflammation in atherosclerosis associated with rheumatoid arthritis.  Am J Med. 2008;  121(10, Suppl 1) S21-S31
  CrossrefPubMedGoogle Scholar
• 68 Nickoloff B J, Xin H, Nestle F O, Qin J Z. The cytokine and chemokine network in psoriasis.  Clin Dermatol. 2007;  25 568-573
  CrossrefPubMedGoogle Scholar
• 69 Croce K, Libby P. Intertwining of thrombosis and inflammation in atherosclerosis.  Curr Opin Hematol. 2007;  14 55-61
  CrossrefPubMedGoogle Scholar
• 70 Späh F. Inflammation in atherosclerosis and psoriasis: common pathogenic mechanisms and the potential for an integrated treatment approach.  Br J Dermatol. 2008;  159(Suppl 2) 10-17
  PubMedGoogle Scholar
• 71 Gisondi P, Fantin F, Del Giglio M et al.. Chronic plaque psoriasis is associated with increased arterial stiffness.  Dermatology. 2009;  218 110-113
  CrossrefPubMedGoogle Scholar
• 72 Ucak S, Ekmekci T R, Basat O, Koslu A, Altuntas Y. Comparison of various insulin sensitivity indices in psoriatic patients and their relationship with type of psoriasis.  J Eur Acad Dermatol Venereol. 2006;  20 517-522
  CrossrefPubMedGoogle Scholar
• 73 Boehncke S, Thaci D, Beschmann H et al.. Psoriasis patients show signs of insulin resistance.  Br J Dermatol. 2007;  157 1249-1251
  CrossrefPubMedGoogle Scholar
• 74 Kaye J A, Li L, Jick S S. Incidence of risk factors for myocardial infarction and other vascular diseases in patients with psoriasis.  Br J Dermatol. 2008;  159 895-902
  CrossrefPubMedGoogle Scholar
• 75 Shapiro J, Cohen A D, David M et al.. The association between psoriasis, diabetes mellitus, and atherosclerosis in Israel: a case-control study.  J Am Acad Dermatol. 2007;  56 629-634
  CrossrefPubMedGoogle Scholar
• 76 Neimann A L, Shin D B, Wang X, Margolis D J, Troxel A B, Gelfand J M. Prevalence of cardiovascular risk factors in patients with psoriasis.  J Am Acad Dermatol. 2006;  55 829-835
  CrossrefPubMedGoogle Scholar
• 77 Cohen A D, Dreiher J, Shapiro Y et al.. Psoriasis and diabetes: a population-based cross-sectional study.  J Eur Acad Dermatol Venereol. 2008;  22 585-589
  CrossrefPubMedGoogle Scholar
• 78 Wolf N, Quaranta M, Prescott N J et al.. Psoriasis is associated with pleiotropic susceptibility loci identified in type II diabetes and Crohn disease.  J Med Genet. 2008;  45 114-116
  PubMedGoogle Scholar
• 79 Wakkee M, Thio H B, Prens E P, Sijbrands E J, Neumann H A. Unfavorable cardiovascular risk profiles in untreated and treated psoriasis patients.  Atherosclerosis. 2007;  190 1-9
  CrossrefPubMedGoogle Scholar
• 80 Rocha-Pereira P, Santos-Silva A, Rebelo I, Figueiredo A, Quintanilha A, Teixeira F. Dislipidemia and oxidative stress in mild and in severe psoriasis as a risk for cardiovascular disease.  Clin Chim Acta. 2001;  303 33-39
  CrossrefPubMedGoogle Scholar
• 81 Mallbris L, Granath F, Hamsten A, Ståhle M. Psoriasis is associated with lipid abnormalities at the onset of skin disease.  J Am Acad Dermatol. 2006;  54 614-621
  CrossrefPubMedGoogle Scholar
• 82 Campalani E, Allen M H, Fairhurst D et al.. Apolipoprotein E gene polymorphisms are associated with psoriasis but do not determine disease response to acitretin.  Br J Dermatol. 2006;  154 345-352
  CrossrefPubMedGoogle Scholar
• 83 Chang C F, Lin C C, Chen J Y et al.. Lipoprotein glomerulopathy associated with psoriasis vulgaris: report of 2 cases with apolipoprotein E3/3.  Am J Kidney Dis. 2003;  42 E18-E23
  CrossrefPubMedGoogle Scholar
• 84 Herron M D, Hinckley M, Hoffman M S et al.. Impact of obesity and smoking on psoriasis presentation and management.  Arch Dermatol. 2005;  141 1527-1534
  CrossrefPubMedGoogle Scholar
• 85 Naldi L, Chatenoud L, Linder D et al.. Cigarette smoking, body mass index, and stressful life events as risk factors for psoriasis: results from an Italian case-control study.  J Invest Dermatol. 2005;  125 61-67
  CrossrefPubMedGoogle Scholar
• 86 Lindegård B. Diseases associated with psoriasis in a general population of 159,200 middle-aged, urban, native Swedes.  Dermatologica. 1986;  172 298-304
  PubMedGoogle Scholar
• 87 Setty A R, Curhan G, Choi H K. Obesity, waist circumference, weight change, and the risk of psoriasis in women: Nurses' Health Study II.  Arch Intern Med. 2007;  167 1670-1675
  CrossrefPubMedGoogle Scholar
• 88 Johnston A, Arnadottir S, Gudjonsson J E et al.. Obesity in psoriasis: leptin and resistin as mediators of cutaneous inflammation.  Br J Dermatol. 2008;  159 342-350
  CrossrefPubMedGoogle Scholar
• 89 Naldi L, Addis A, Chimenti S et al.. Impact of body mass index and obesity on clinical response to systemic treatment for psoriasis. Evidence from the Psocare project.  Dermatology. 2008;  217 365-373
  CrossrefPubMedGoogle Scholar
• 90 Gisondi P, Del Giglio M, Di Francesco V, Zamboni M, Girolomoni G. Weight loss improves the response of obese patients with moderate-to-severe chronic plaque psoriasis to low-dose cyclosporine therapy: a randomized, controlled, investigator-blinded clinical trial.  Am J Clin Nutr. 2008;  88 1242-1247
  PubMedGoogle Scholar
• 91 Grundy S M, Brewer Jr H B, Cleeman J I, Smith Jr S C, Lenfant C. American Heart Association . Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition.  Circulation. 2004;  109 433-438
  CrossrefPubMedGoogle Scholar
• 92 National Institute of Health .Third Report of the National Cholesterol Education Program Export Panel on Detection, Evaluation, and Treatment of High Blood cholesterol in Adults (Adult Treament Panel III). Executive Summary. Bethesda, MD; National Institute of Health, National Hearth, Lung and Blood Institute 2001 NIH Publ. No. 01–3670
  Google Scholar
• 93 Gisondi P, Tessari G, Conti A et al.. Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based case-control study.  Br J Dermatol. 2007;  157 68-73
  CrossrefPubMedGoogle Scholar
• 94 Sommer D M, Jenisch S, Suchan M, Christophers E, Weichenthal M. Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis.  Arch Dermatol Res. 2006;  298 321-328
  CrossrefPubMedGoogle Scholar
• 95 Levi M, Nieuwdorp M, van der Poll T, Stroes E. Metabolic modulation of inflammation-induced activation of coagulation.  Semin Thromb Hemost. 2008;  34 26-32
  Article in Thieme ConnectPubMedGoogle Scholar
• 96 Nieuwdorp M, Stroes E S, Meijers J C, Büller H. Hypercoagulability in the metabolic syndrome.  Curr Opin Pharmacol. 2005;  5 155-159
  CrossrefPubMedGoogle Scholar
• 97 Naldi L. Cigarette smoking and psoriasis.  Clin Dermatol. 1998;  16 571-574
  CrossrefPubMedGoogle Scholar
• 98 Bø K, Thoresen M, Dalgard F. Smokers report more psoriasis, but not atopic dermatitis or hand eczema: results from a Norwegian population survey among adults.  Dermatology. 2008;  216 40-45
  CrossrefPubMedGoogle Scholar
• 99 Favato G. High incidence of smoking habit in psoriatic patients.  Am J Med. 2008;  121 e17
  PubMedGoogle Scholar
• 100 ISTAT .Health for all. Available at: http://www.istat.it/sanita/Health Accessed February 20, 2009
  Google Scholar
• 101 Setty A R, Curhan G, Choi H K. Smoking and the risk of psoriasis in women: Nurses' Health Study II.  Am J Med. 2007;  120 953-959
  CrossrefPubMedGoogle Scholar
• 102 Prodanovich S, Prodanowich S, Ma F et al.. Methotrexate reduces incidence of vascular diseases in veterans with psoriasis or rheumatoid arthritis.  J Am Acad Dermatol. 2005;  52 262-267
  CrossrefPubMedGoogle Scholar
• 103 Warren R B, Griffiths C E. Systemic therapies for psoriasis: methotrexate, retinoids, and cyclosporine.  Clin Dermatol. 2008;  26 438-447
  CrossrefPubMedGoogle Scholar
• 104 Antoniou C, Dessinioti C, Katsambas A, Stratigos A J. Elevated triglyceride and cholesterol levels after intravenous antitumour necrosis factor-alpha therapy in a patient with psoriatic arthritis and psoriasis vulgaris.  Br J Dermatol. 2007;  156 1090-1091
  CrossrefPubMedGoogle Scholar
• 105 Stinco G, Piccirillo F, Patrone P. Hypertriglyceridaemia during treatment with adalimumab in psoriatic arthritis.  Br J Dermatol. 2007;  157 1273-1274
  CrossrefPubMedGoogle Scholar
• 106 Dixon W G, Watson K D, Lunt M, Hyrich K L, Silman A J, Symmons D P. British Society for Rheumatology Biologics Register Control Centre Consortium . Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register.  Arthritis Rheum. 2007;  56 2905-2912
  CrossrefPubMedGoogle Scholar
• 107 Bosello S, Santoliquido A, Zoli A et al.. TNF-alpha blockade induces a reversible but transient effect on endothelial dysfunction in patients with long-standing severe rheumatoid arthritis.  Clin Rheumatol. 2008;  27 833-839
  CrossrefPubMedGoogle Scholar

Dr. Paolo Gisondi

Department of Biomedical and Surgical Science, Section of Dermatology and Venereology

University of Verona, Piazzale A. Stefani, 1, 37126 Verona, Italy

Email: paolo.gisondi@univr.it